Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer

This study is looking at whether using a faster type of MRI called bpMRI will improve prostate cancer screening and lead to earlier detection of prostate cancer in high risk men. The study is enrolling men with an ATM, BRCA1, BRCA2, CHEK2, HOX B13, or Lynch syndrome mutation.

Compared with traditional MRI which requires an intravenous injection of gadalinium contrast, bpMRI requires no contrast and is faster, more cost-effective, and less invasive.

This study will use bpMRI in conjunction with PSA screening for the early detection of prostate cancer in high-risk men.   

• All study participants will undergo a bpMRI.
• Study participants with negative bpMRI will be followed with annual PSA screening.
• Study participants with a positive bpMRI will have a prostate biopsy performed.
  • Those with a benign biopsy will be followed with annual PSA screening.
  • Those who have a biopsy positive for cancer will be managed and followed according to the standard of care.
• Study participants will be followed for 5 years.

Men 40 years to 55 years may be eligible if they:

1. have a PSA between 1.0 and 2.5 ng/dL.
2. are considered at high-risk for prostate cancer, including any of the following:
   • are Black,
   • have a first-degree relative (father, brother or son) with prostate cancer, or
   • have an inherited mutation in ATM, BRCA1, BRCA2, CHEK2, HOXB13 or any of the Lynch syndrome genes (EPCAM, MLH1, MSH2, MSH6, PMS2).

Men are not eligible to participate if they:

• have one or more firm lumps or hardened areas on the prostate gland.
• have already had a prior biopsy or prostate surgery.  
• are taking a testosterone blocker.
• are unable to undergo an MRI.